Logo
x

Search

Subscribe Now

EGFR-Mutated

Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung Cancer

Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung C...

  • September 29, 2023
Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC at IASLC 2023 WCLC

Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC...

  • September 12, 2023
AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso for EGFR-Mutated Advanced Lung Cancer

AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso for EGFR-Mutated Advanced Lung Cancer

  • September 12, 2023
Daiichi Sankyo Presents P-II Trial (HERTHENA-Lung01) Results of Patritumab Deruxtecan for EGFR-Mutated Metastatic NSCLC at WCLC 2023

Daiichi Sankyo Presents P-II Trial (HERTHENA-Lung01) Results of Patritumab Deruxtecan for EGFR-Mutated Metastatic NSCLC at WCLC 20...

  • September 11, 2023
Innovent and Eli Lilly Receive the NMPA’s Approval of Tyvyt (sintilimab) sNDA for EGFR-Mutated Non-Squamous NSCLC 

Innovent and Eli Lilly Receive the NMPA’s Approval of Tyvyt (sintilimab) sNDA for EGFR-Mutated Non-Squamous NSCLC 

  • May 11, 2023
Innovent Reports P-III Study (ORIENT-31) Results of Sintilimab for EGFR-TKI Failed EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Innovent Reports P-III Study (ORIENT-31) Results of Sintilimab for EGFR-TKI Failed EGFR-Mutated Non-Squamous Non-Small Cell Lung C...

  • May 8, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.